MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 528606 | Name: Org-25935

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Org-25935, also called SCH-900435, is a GlyT-1 inhibitor potentially for the treatment of schizophrenia and alcohol dependence.

Chemical Structure

Org-25935
Org-25935
CAS#949588-40-3 (HCl)

Theoretical Analysis

MedKoo Cat#: 528606

Name: Org-25935

CAS#: 949588-40-3 (HCl)

Chemical Formula: C21H26ClNO3

Exact Mass:

Molecular Weight: 375.89

Elemental Analysis: C, 67.10; H, 6.97; Cl, 9.43; N, 3.73; O, 12.77

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
754965-07-6 (Free base)
Synonym
Org-25935; SCH-900435; Org 25935; SCH 900435; Org 25935; SCH 900435
IUPAC/Chemical Name
N-(((1R,2S)-6-methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl)methyl)-N-methylglycine hydrochloride
InChi Key
SDTLOODMXMDJFX-JKSHRDEXSA-N
InChi Code
InChI=1S/C21H25NO3.ClH/c1-22(14-20(23)24)13-17-9-8-16-12-18(25-2)10-11-19(16)21(17)15-6-4-3-5-7-15;/h3-7,10-12,17,21H,8-9,13-14H2,1-2H3,(H,23,24);1H/t17-,21+;/m1./s1
SMILES Code
O=C(O)CN(C)C[C@@H]1[C@H](c2ccccc2)c3ccc(OC)cc3CC1.Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 375.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Christmas D, Diaper A, Wilson S, Rich A, Phillips S, Udo de Haes J, Sjogren M, Nutt D. A randomised trial of the effect of the glycine reuptake inhibitor Org 25935 on cognitive performance in healthy male volunteers. Hum Psychopharmacol. 2014 Mar;29(2):163-71. PubMed PMID: 24424780. 2: de Bejczy A, Nations KR, Szegedi A, Schoemaker J, Ruwe F, Söderpalm B. Efficacy and safety of the glycine transporter-1 inhibitor org 25935 for the prevention of relapse in alcohol-dependent patients: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res. 2014 Sep;38(9):2427-35. doi: 10.1111/acer.12501. PubMed PMID: 25257291. 3: Motoyama N, Morita K, Shiraishi S, Kitayama T, Kanematsu T, Uezono Y, Dohi T. Relief of cancer pain by glycine transporter inhibitors. Anesth Analg. 2014 Oct;119(4):988-95. doi: 10.1213/ANE.0000000000000388. PubMed PMID: 25076101. 4: Schoemaker JH, Jansen WT, Schipper J, Szegedi A. The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial. J Clin Psychopharmacol. 2014 Apr;34(2):190-8. doi: 10.1097/JCP.0000000000000073. PubMed PMID: 24525661. 5: Nations KR, Smits JA, Tolin DF, Rothbaum BO, Hofmann SG, Tart CD, Lee A, Schipper J, Sjogren M, Xue D, Szegedi A, Otto MW. Evaluation of the glycine transporter inhibitor Org 25935 as augmentation to cognitive-behavioral therapy for panic disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2012 May;73(5):647-53. doi: 10.4088/JCP.11m07081. Epub 2012 Feb 21. PubMed PMID: 22394471. 6: Lidö HH, Stomberg R, Fagerberg A, Ericson M, Söderpalm B. The glycine reuptake inhibitor org 25935 interacts with basal and ethanol-induced dopamine release in rat nucleus accumbens. Alcohol Clin Exp Res. 2009 Jul;33(7):1151-7. doi: 10.1111/j.1530-0277.2009.00938.x. Epub 2009 Apr 9. PubMed PMID: 19389199. 7: Molander A, Lidö HH, Löf E, Ericson M, Söderpalm B. The glycine reuptake inhibitor Org 25935 decreases ethanol intake and preference in male wistar rats. Alcohol Alcohol. 2007 Jan-Feb;42(1):11-8. Epub 2006 Nov 9. PubMed PMID: 17098748. 8: D'Souza DC, Singh N, Elander J, Carbuto M, Pittman B, Udo de Haes J, Sjogren M, Peeters P, Ranganathan M, Schipper J. Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence. Neuropsychopharmacology. 2012 Mar;37(4):1036-46. doi: 10.1038/npp.2011.295. Epub 2011 Nov 23. PubMed PMID: 22113087; PubMed Central PMCID: PMC3280648. 9: Castner SA, Murthy NV, Ridler K, Herdon H, Roberts BM, Weinzimmer DP, Huang Y, Zheng MQ, Rabiner EA, Gunn RN, Carson RE, Williams GV, Laruelle M. Relationship between glycine transporter 1 inhibition as measured with positron emission tomography and changes in cognitive performances in nonhuman primates. Neuropsychopharmacology. 2014 Nov;39(12):2742-9. doi: 10.1038/npp.2014.4. Epub 2014 Feb 3. PubMed PMID: 24487737; PubMed Central PMCID: PMC4200505. 10: Chue P. Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1). Curr Pharm Des. 2013;19(7):1311-20. Review. PubMed PMID: 23194655. 11: Jardemark K, Marcus MM, Malmerfelt A, Shahid M, Svensson TH. Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission. Psychopharmacology (Berl). 2012 May;221(1):115-31. doi: 10.1007/s00213-011-2554-3. Epub 2011 Nov 9. PubMed PMID: 22068461. 12: Chau P, Stomberg R, Fagerberg A, Söderpalm B, Ericson M. Glycine receptors involved in acamprosate's modulation of accumbal dopamine levels: an in vivo microdialysis study. Alcohol Clin Exp Res. 2010 Jan;34(1):32-8. doi: 10.1111/j.1530-0277.2009.01062.x. Epub 2009 Oct 23. PubMed PMID: 19860810. 13: Kalinichev M, Starr KR, Teague S, Bradford AM, Porter RA, Herdon HJ. Glycine transporter 1 (GlyT1) inhibitors exhibit anticonvulsant properties in the rat maximal electroshock threshold (MEST) test. Brain Res. 2010 May 17;1331:105-13. doi: 10.1016/j.brainres.2010.03.032. Epub 2010 Mar 18. PubMed PMID: 20303337.

View History

3-Methyltoxoflavin

3-Methyltoxoflavin

Tan 1120

Tan 1120

Camostat free base

Camostat free base

Labuxtinib

Labuxtinib